Yi Lin, M.D., Ph.D., is a hematologist and oncologist with a clinical practice in lymphoma, multiple myeloma and cell therapy. Dr. Lin also conducts research on cancer, including cancer vaccines and cancer immunotherapy. She has served as a principal investigator on multiple cell therapy clinical trials, including the registration studies that led to approval by the U.S. Food and Drug Administration (FDA) of axicabtagene ciloleucel (Yescarta), idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti). Dr. Lin also has received funding from the National Institutes of Health (NIH) to conduct translational research on novel cancer immunotherapy development and biomarkers of predictors of response and toxicities in immunotherapy.